Apple, Mylan lose Supreme Court bids to challenge patent review rule

The U.S. Supreme Court on Tuesday turned back challenges by Apple Inc and drugmaker Mylan Laboratories Ltd to a rule change that made it harder to contest patents before the U.S. Patent and Trademark Office.

Neurim Can't Stop Mylan From Restarting Melatonin Fight - Law360

Generic-drug maker Mylan is free to challenge the validity of Israeli pharmaceutical company Neurim's melatonin patent at an upcoming trial after a London judge ruled Monday that it did not run afoul of procedural rules about the timing of an...

Mylan Loses Bid To Stall Trial Over Neurim's Melatonin Patent - Law360

A judge has refused generic-drug maker Mylan's request to stay Neurim's patent infringement litigation to wait for a European Patent Office ruling on the validity of the Israeli pharmaceutical company's melatonin patent, saying on Friday that the...

Neurim v Mylan: Take Two

Last we heard about the Neurim v Mylan battle, Mylan had the upper-hand. But the recent grant of a divisional patent to Neurim has, perhaps, turned the tables on Mylan.